Pharma M&A Deals Totaling $14.8 Billion in November 2024
In November 2024, the pharma and healthcare industry saw a total of 95 deals amounting to $14.8 billion. This is slightly lower than the average of 102 deals worth $16.8 billion over the last 12 months.
Some notable deals include Hoffmann-La Roche acquiring Poseida Therapeutics for $1.5 billion, Ampersand Capital Partners and GHO Capital Partners acquiring Avid Bioservices for about $1.1 billion, and Novartis AG acquiring Kate Therapeutics for up to $1.1 billion. Together, these three deals made up 25% of the total deal value for the month.
In terms of venture capital investments, the healthcare industry reported 85 deals worth $1.9 billion in November 2024, compared to the 12-month average of 105 deals worth $2.8 billion.
Some significant VC deals included Metsera raising $215 million, Alentis Therapeutics AG raising $181.4 million, and ADCendo ApS raising $135 million. These deals are focused on advancing clinical-stage biopharmaceuticals and biotechnology research.
Overall, the industry continues to see robust activity in mergers and acquisitions as well as venture capital investments, indicating a strong market environment.
